Nanobodies: From High-Throughput Identification to Therapeutic Development

Area of Science:

• Biotechnology and Pharmaceutical Sciences
• Immunology and Infectious Diseases

Background:

• Camelid single-domain antibody fragments (nanobodies) offer advantages over conventional monoclonal antibodies (mAbs) due to their small size (~15 kDa), structural simplicity, and high stability.
• Nanobodies are emerging as valuable tools in biologic development, complementing mAb therapies for autoimmune diseases, cancer, and infectious diseases like COVID-19.

Purpose of the Study:

• To highlight the advantages of using a proteomic approach to identify diverse nanobody sequences against a single antigen.
• To underscore the benefits of generating large, diverse nanobody repertoires for comprehensive antigen sampling and synergistic activity.
• To review recent findings on nanobody structural attributes facilitating antigen binding and clinical development efforts.

Main Methods:

• Integration of a proteomic approach with conventional yeast/phage display methods for nanobody repertoire generation.
• Analysis of nanobody structural attributes relevant to antigen binding and epitope landscape coverage.

Main Results:

• Proteomic approaches coupled with display technologies enable the production of highly diverse nanobody repertoires.
• Nanobodies demonstrate superior epitope sampling compared to mAbs, accessing a broader range of antigenic sites.
• Structural characteristics of nanobodies facilitate extensive antigen interaction and potential for synergistic therapeutic effects.

Conclusions:

• A proteomic strategy combined with display methods is effective for generating diverse nanobody repertoires against single antigens.
• Nanobodies offer significant potential as diagnostic reagents and therapeutic agents, particularly for rapidly evolving infectious disease targets.
• Ongoing clinical development highlights the promise of nanobodies as next-generation biologics.